Polymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma

Melanoma Research

Volumn 19, Issue 2, 2009, Pages 80-86

  Zhao, Zhen Zhen ^a   Duffy, David L ^a   Thomas, Shane A ^a   Martin, Nicholas G ^a   Hayward, Nicholas K ^a   Montgomery, Grant W ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SYNTAXIN; SYNTAXIN 17; UNCLASSIFIED DRUG; CHAPERONE; DNA BINDING PROTEIN; INVS PROTEIN, HUMAN; MEMBRANE PROTEIN; NR4A3 PROTEIN, HUMAN; STEROID RECEPTOR; THYROID HORMONE RECEPTOR; TRANSCRIPTION FACTOR; TXNDC4 PROTEIN, HUMAN;

ARTICLE; AUSTRALIA; CANCER RISK; CHROMOSOME 20; CONTROLLED STUDY; CUTANEOUS MALIGNANT MELANOMA; GENE ASSIGNMENT; GENE INTERACTION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MELANOMA; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; ANIMAL; ANIMAL DISEASE; CASE CONTROL STUDY; CHROMOSOME 9; COMPARATIVE STUDY; FACE TUMOR; GENETICS; HORSE; HORSE DISEASE; PHYSIOLOGY; SKIN TUMOR; SPECIES DIFFERENCE;

ANIMALS; AUSTRALIA; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 9; DNA-BINDING PROTEINS; FACIAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HORSE DISEASES; HORSES; HUMANS; MELANOMA; MEMBRANE PROTEINS; MOLECULAR CHAPERONES; POLYMORPHISM, SINGLE NUCLEOTIDE; QA-SNARE PROTEINS; RECEPTORS, STEROID; RECEPTORS, THYROID HORMONE; SKIN NEOPLASMS; SPECIES SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 65449130074     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328322fc45     Document Type: Article

References (40)

1. Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv 1994; 19-20:219-240.
2. Berwick M, Wiggins C. The current epidemiology of cutaneous malignant melanoma. Front Biosci 2006; 11:1244-1254.
3. Ford D, Bliss JM, Swerdlow AJ, Armstrong BK, Franceschi S, Green A, et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62: 377-381.
4. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003; 22 :3053-3062.
5. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15-21.
6. Koh HK, Kligler BE, Lew RA. Sunlight and cutaneous malignant melanoma: evidence for and against causation. Photochem Photobiol 1990; 51 :765-779.
7. Lejeune FJ. Epidemiology and etiology of malignant melanoma. Biomed Pharmacother 1986; 40:91-99.
8. Lynch HT, Fusaro RM. Hereditary malignant melanoma: a unifying etiologic hypothesis. Cancer Genet Cytogenet 1986; 20:301-304.
9. De Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 2005; 230:153-186.
10. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006; 313:521-522.
11. Pollock PM, Walker GJ, Glendening JM, Que Noy T, Bloch NC, Fountain JW, et al. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res 2002; 12:565-575.
12. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12:97-99.
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
14. Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, et al. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 1995; 10:114-116.
15. Brown KM, Macgregor S, Montgomery GW, Craig DW, Zhao ZZ, Iyadurai K, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008; 40:838-840.
16. Rosengren Pielberg G, Golovko A, Sundstrom E, Curik I, Lennartsson J, Seltenhammer MH, et al. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. Nat Genet 2008; 40 :1004-1009.
17. Locke MM, Penedo MC, Bricker SJ, Millon LV, Murray JD. Linkage of the grey coat colour locus to microsatellites on horse chromosome 25. Anim Genet 2002; 33:329-337.
18. Pielberg G, Mikko S, Sandberg K, Andersson L. Comparative linkage mapping of the grey coat colour gene in horses. Anim Genet 2005; 36 :390-395.
19. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258:1148-1152.
20. Zhu G, Montgomery GW, James MR, Trent JM, Hayward NK, Martin NG, et al. A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions. Eur J Hum Genet 2007; 15 :94-102.
21. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2007; 67:2632-2642.
22. Steegmaier M, Oorschot V, Klumperman J, Scheller RH. Syntaxin 17 is abundant in steroidogenic cells and implicated in smooth endoplasmic reticulum membrane dynamics. Mol Biol Cell 2000; 11:2719-2731.
23. Zhang Q, Li J, Deavers M, Abbruzzese JL, Ho L. The subcellular localization of syntaxin 17 varies among different cell types and is altered in some malignant cells. J Histochem Cytochem 2005; 53: 1371-1382.
24. Baxter AJ, Hughes MC, Kvaskoff M, Siskind V, Shekar S, Aitken JF, et al. The Queensland Study of Melanoma: environmental and genetic associations (Q-MEGA); study design, baseline characteristics, and repeatability of phenotype and sun exposure measures. Twin Res Hum Genet 2008; 11 :183-196.
25. Zhu G, Duffy DL, Eldridge A, Grace M, Mayne C, O'Gorman L, et al. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet 1999; 65 :483-492.
26. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16 :1215.
27. Zhao ZZ, Nyholt DR, Le L, Martin NG, James MR, Treloar SA, et al. KRAS variation and risk of endometriosis. Mol Hum Reprod 2006; 12 :671-676.
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
29. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229.
30. Kooperberg C, Ruczinski I. Identifying interacting SNPs using Monte Carlo logic regression. Genet Epidemiol 2005; 28:157-170.
31. Schwender H, Ickstadt K. Identification of SNP interactions using logic regression. Biostatistics 2008; 9:187-198.
32. Nyholt DR. ssSNPer: identifying statistically similar SNPs to aid interpretation of genetic association studies. Bioinformatics 2006; 22 :2960-2961.
33. Maxwell MA, Muscat GE. The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl Recept Signal 2006; 4 :e002.
34. Hoersch B, Leiter U, Garbe C. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol 2006; 155:771-777.
35. Green A. A theory of site distribution of melanomas: Queensland, Australia. Cancer Causes Control 1992; 3:513-516.
36. Green A, Beardmore G, Hart V, Leslie D, Marks R, Staines D. Skin cancer in a Queensland population. J Am Acad Dermatol 1988; 19:1045-1052.
37. Chen YT, Dubrow R, Holford TR, Zheng T, Barnhill RL, Fine J, et al. Malignant melanoma risk factors by anatomic site: a case-control study and polychotomous logistic regression analysis. Int J Cancer 1996; 67:636-643.
38. Randi G, Naldi L, Gallus S, Di Landro A, La Vecchia C. Number of nevi at a specific anatomical site and its relation to cutaneous malignant melanoma. J Invest Dermatol 2006; 126:2106-2110.
39. Rieger E, Soyer HP, Garbe C, Buttner P, Kofler R, Weiss J, et al. Overall and site-specific risk of malignant melanoma associated with nevus counts at different body sites: a multicenter case-control study of the German Central Malignant-Melanoma Registry. Int J Cancer 1995; 62:393-397.
40. Rodenas JM, Delgado-Rodriguez M, Farinas-Alvarez C, Herranz MT, Serrano S. Melanocytic nevi and risk of cutaneous malignant melanoma in southern Spain. Am J Epidemiol 1997; 145:1020-1109.